ICLR
ICON Public Limited Company
There isn't enough reported data to score ICLR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ICLR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Stable |
ICLR's revenue and cash flow are currently healthy, and its profitability and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICLR PE Valuation
ICLR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ICLR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect ICLR's earnings, revenue and profitability to hold roughly steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ICLR on the outlook, with more favorable earnings and revenue expectations.
ICLR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +288% |
| Q4 2025 | $2.90 | -70% |
| Q3 2025 | $7.39 | -18% |
| Q2 2025 | $9.72 | +13% |
| Q1 2025 | $9.18 | +11% |
| Q4 2024 | $9.53 | +29% |
| Q3 2024 | $8.99 | +45% |
| Q2 2024 | $8.60 | +39% |
| Q1 2024 | $8.24 | +33% |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 70% for ICLR versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ICLR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2B | -0.9% |
| Q2 2026 | $2.1B | +2.3% |
| Q1 2026 | $2B | +1.6% |
| Q4 2025 | $8.3B | +304% |
| Q3 2025 | $2B | +0.6% |
| Q2 2025 | $2B | -4.8% |
| Q1 2025 | $2B | -4.3% |
| Q4 2024 | $2B | -1.2% |
ICLR's revenue has picked up after three years of holding roughly level: $2B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +5.6 points |
| Q2 2026 | 6.7% | -3.7 points |
| Q1 2026 | 8.5% | -2.4 points |
| Q4 2025 | 5.4% | -9.2 points |
| Q3 2025 | 4.2% | -9.8 points |
| Q2 2025 | 10% | -0.5 points |
| Q1 2025 | 11% | -2.7 points |
| Q4 2024 | 15% | +1.7 points |
ICLR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ICLR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ICLR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $307.1M | -8% |
| Q2 2026 | $238.8M | +110% |
| Q1 2026 | $136.2M | -43% |
| Q4 2025 | $862M | +211% |
| Q3 2025 | $333.9M | -7.1% |
| Q2 2025 | $113.9M | -38% |
| Q1 2025 | $239.3M | -20% |
| Q4 2024 | $277M | -28% |
ICLR generated $1.5B in free cash flow over the past year, up 60% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ICLR on cash flow, with more consistent year-over-year improvement.
ICLR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +32.7K shares |
| 1 year | -0.9% | -678K shares |
| 3 years | -6.7% | -5.6M shares |
| 5 years | -4.2% | -3.4M shares |
| Available history | +42% | +23.1M shares |
ICLR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $750M |
| Q3 2025 | $250M |
| Q2 2025 | $250M |
| Q1 2025 | $250M |
| Q4 2024 | $400M |
ICLR spent $1.1B buying back its own shares over the past year, about the same as the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ICLR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.0x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 1.8x | Healthy |
| Q3 2024 | 1.7x | Healthy |
| Q2 2024 | 1.8x | Healthy |
| Q1 2024 | 1.9x | Healthy |
ICLR's net debt is about 2.7 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ICLR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 79.3 | Neutral |
ICLR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ICLR PE vs Healthcare Sector
| Metric | ICLR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ICLR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ICLR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.8 | 9.1% above |
| 20 week MA | $173.9 | 15% above |
| 50 week MA | $152.9 | 31% above |
| 100 week MA | $161.8 | 24% above |
| 200 week MA | $213.5 | 6.1% below |
ICLR has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 6.1% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ICLR on trend strength, trading above more of its moving averages.
ICLR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $171.9 | $192.5 | +12% |
| 2021 | $192.5 | $307.9 | +60% |
| 2022 | $307.9 | $194.9 | -37% |
| 2023 | $194.9 | $283.1 | +45% |
| 2024 | $283.1 | $212.3 | -25% |
| 2025 | $212.3 | $182.8 | -14% |
| 2026 YTD | $182.8 | $200.5 | +9.7% |
ICLR has finished lower in three of the last six years. It's up 9.7% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ICLR on returns for 2026, with the stronger performance.